宝利化（南京）制药有限公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
8
NMPA:8
Drug Approvals
Neostigmine Methylsulfate Injection
- Product Name
- 甲硫酸新斯的明注射液
- Approval Number
- 国药准字H20254190
- Approval Date
- May 20, 2025
NMPA
Neostigmine Methylsulfate Injection
- Product Name
- 甲硫酸新斯的明注射液
- Approval Number
- 国药准字H20254179
- Approval Date
- May 13, 2025
NMPA
Dihydroergotoxine Methanesulfonate Sustained Release Tablets
- Product Name
- 甲磺酸二氢麦角碱缓释片
- Approval Number
- 国药准字H20093234
- Approval Date
- Sep 7, 2023
NMPA
Xanthinol Nicotinate Injection
- Product Name
- 烟酸占替诺注射液
- Approval Number
- 国药准字H20065849
- Approval Date
- Mar 25, 2021
NMPA
Levetiracetam Concentrated Solution for Injection
- Product Name
- 左乙拉西坦注射用浓溶液
- Approval Number
- 国药准字H20213170
- Approval Date
- Mar 9, 2021
NMPA
Xanthinol Nicotinate Tablets
- Product Name
- 烟酸占替诺片
- Approval Number
- 国药准字H20093840
- Approval Date
- Jul 12, 2019
NMPA
Clinical Trials
No trials found
News
No news found